People · Operator

Nathan L. Raulin

Named in public records as an officer, director or promoter · active 2015–2016 · Hospitals and Physicians, Other Health Care

2
Companies
3
Filings
$122.4M
Combined raised · real
Serial
Operator type
Companies
CompanyRoleSectorStageRaised · realValue · estTied
Premier Imaging Holdings, LLCHospitals and PhysiciansSeries C$86.7M$1.8B2016
Mentis Holdings, LLCOther Health CareSeries B$35.8M$28.8M2015
Operator network

Nathan L. Raulin at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.

David L. Kessenich · 3 companies · 1 sharedDavid L. KessenichDouglas Reader · 1 companies · 1 sharedDouglas ReaderMark Alfonso · 1 companies · 1 sharedMark AlfonsoPatrick L. O'Keefe · 1 companies · 1 sharedPatrick L. O'KeefeRobert A. Martin · 4 companies · 1 sharedRobert A. MartinC. Ryan Glaws · 3 companies · 1 sharedC. Ryan GlawsChantell L. Preston · 2 companies · 1 sharedChantell L. Prest…Cindy L. Ivanhoe, M.D. · 1 companies · 1 sharedCindy L. Ivanhoe,…Jerome A. Mee · 1 companies · 1 sharedJerome A. MeeMark L. Quigley · 1 companies · 1 sharedMark L. QuigleyRyan C Glaws · 1 companies · 1 sharedRyan C GlawsPremier Imaging Holdings, LLC · $86.7M raisedPremier Imaging Holdi…Mentis Holdings, LLC · $35.8M raisedMentis Holdings, LLCNathan L. RaulinNR
Nathan L. Raulin Company Co-operator (ring = serial)Hover to isolate ties · click to open
Co-operators (shared boards)

People named alongside Nathan L. Raulin on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.

OperatorSharedTheir companies
Robert A. Martin14
David L. Kessenich13
C. Ryan Glaws13
Chantell L. Preston12
Ryan C Glaws11
Mark Alfonso11
Patrick L. O'Keefe11
Douglas Reader11
Mark L. Quigley11
Jerome A. Mee11
Cindy L. Ivanhoe, M.D.11

People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.